Outsourcing Against the Outbreak Episodes

1. Calculating Outbreaks Early Through Advanced Surveillance 10/5/2026

   Effective outbreak response begins long before a vaccine or therapeutic enters manufacturing; it relies on early detection of emerging pathogens and continuous surveillance during quiet periods. In this episode of Outsourcing Against the Outbreak, Dr. Al Ozonoff, Associate Professor of Pediatrics at Harvard Medical School and Senior Director of Pandemic Preparedness at the Broad Institute, discusses how biostatistics and mathematical modeling power global disease surveillance. The conversation explores the Sentinel program, an international early-warning framework co-led with Nigeria's Institute of Genomics and Global Health, and how its genomic surveillance model was tested during the 2025 Mpox outbreak in Sierra Leone. Dr. Ozonoff details the logistical and governance realities of expanding surveillance capabilities across Africa, why biopharma developers must engage local partners prior to a crisis, and how transferring technology and source code to national institutions creates long-term, sustainable public health infrastructure.

2. Expanding Global Access Through Voluntary Licensing and Tech Transfer 8/25/2026

   Turning patented biomedical discoveries into affordable, widely available treatments requires aligned partnerships between innovator pharma and regional generic manufacturers. In this episode of Outsourcing Against the Outbreak, Charles Gore, Executive Director of the Medicines Patent Pool (MPP), breaks down how voluntary licensing models expand access across low- and middle-income markets.

3. Advancing Academic Vaccine Innovation into Global Access 8/25/2026

   Moving infectious disease programs from promising laboratory discoveries to scalable interventions requires bridging the gap between academic research and commercial manufacturing. In this episode of Outsourcing Against the Outbreak, Dr. Maria Elena Bottazzi, Co-Director of the Texas Children's Hospital Center for Vaccine Development at Baylor College of Medicine, explores how academic teams can navigate this journey successfully.

4. Great Science Isn't Enough: Solving The Global Health Drug Development Equation 8/25/2026

   Designing infectious disease interventions for low- and middle-income countries requires solving for access, affordability, and delivery from day one rather than treating them as downstream afterthoughts. In this inaugural episode of Outsourcing Against the Outbreak, Dr. Krishnan Ramanathan, Interim CEO of the Gates Medical Research Institute (Gates MRI), explores how to navigate the unique economic and operational realities of global health R&D.